193 related articles for article (PubMed ID: 10741859)
1. Complement receptor type two (CR2,CR21): a target for influencing the humoral immune response and antigen-trapping.
Prodinger WM
Immunol Res; 1999; 20(3):187-94. PubMed ID: 10741859
[TBL] [Abstract][Full Text] [Related]
2. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface.
Guthridge JM; Young K; Gipson MG; Sarrias MR; Szakonyi G; Chen XS; Malaspina A; Donoghue E; James JA; Lambris JD; Moir SA; Perkins SJ; Holers VM
J Immunol; 2001 Nov; 167(10):5758-66. PubMed ID: 11698449
[TBL] [Abstract][Full Text] [Related]
3. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus.
Asokan R; Hua J; Young KA; Gould HJ; Hannan JP; Kraus DM; Szakonyi G; Grundy GJ; Chen XS; Crow MK; Holers VM
J Immunol; 2006 Jul; 177(1):383-94. PubMed ID: 16785534
[TBL] [Abstract][Full Text] [Related]
4. Biophysical investigations of complement receptor 2 (CD21 and CR2)-ligand interactions reveal amino acid contacts unique to each receptor-ligand pair.
Kovacs JM; Hannan JP; Eisenmesser EZ; Holers VM
J Biol Chem; 2010 Aug; 285(35):27251-27258. PubMed ID: 20558730
[TBL] [Abstract][Full Text] [Related]
5. Genetic CD21 deficiency is associated with hypogammaglobulinemia.
Thiel J; Kimmig L; Salzer U; Grudzien M; Lebrecht D; Hagena T; Draeger R; Voelxen N; Bergbreiter A; Jennings S; Gutenberger S; Aichem A; Illges H; Hannan JP; Kienzler AK; Rizzi M; Eibel H; Peter HH; Warnatz K; Grimbacher B; Rump JA; Schlesier M
J Allergy Clin Immunol; 2012 Mar; 129(3):801-810.e6. PubMed ID: 22035880
[TBL] [Abstract][Full Text] [Related]
6. Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21).
Young KA; Chen XS; Holers VM; Hannan JP
J Biol Chem; 2007 Dec; 282(50):36614-25. PubMed ID: 17925391
[TBL] [Abstract][Full Text] [Related]
7. The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21).
Hannan JP
Curr Protein Pept Sci; 2016; 17(5):463-87. PubMed ID: 26916158
[TBL] [Abstract][Full Text] [Related]
8. Regulation of humoral immunity by complement.
Carroll MC; Isenman DE
Immunity; 2012 Aug; 37(2):199-207. PubMed ID: 22921118
[TBL] [Abstract][Full Text] [Related]
9. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection.
Carel JC; Myones BL; Frazier B; Holers VM
J Biol Chem; 1990 Jul; 265(21):12293-9. PubMed ID: 1695627
[TBL] [Abstract][Full Text] [Related]
10. Structure of complement receptor 2 in complex with its C3d ligand.
Szakonyi G; Guthridge JM; Li D; Young K; Holers VM; Chen XS
Science; 2001 Jun; 292(5522):1725-8. PubMed ID: 11387479
[TBL] [Abstract][Full Text] [Related]
11. Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis.
Kovacs JM; Hannan JP; Eisenmesser EZ; Holers VM
J Biol Chem; 2009 Apr; 284(14):9513-20. PubMed ID: 19164292
[TBL] [Abstract][Full Text] [Related]
12. Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220.
Sarrias MR; Franchini S; Canziani G; Argyropoulos E; Moore WT; Sahu A; Lambris JD
J Immunol; 2001 Aug; 167(3):1490-9. PubMed ID: 11466369
[TBL] [Abstract][Full Text] [Related]
13. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21).
Clemenza L; Isenman DE
J Immunol; 2000 Oct; 165(7):3839-48. PubMed ID: 11034390
[TBL] [Abstract][Full Text] [Related]
14. The Epstein-Barr virus-binding site on CD21 is involved in CD23 binding and interleukin-4-induced IgE and IgG4 production by human B cells.
Henchoz-Lecoanet S; Jeannin P; Aubry JP; Graber P; Bradshaw CG; Pochon S; Bonnefoy JY
Immunology; 1996 May; 88(1):35-9. PubMed ID: 8707347
[TBL] [Abstract][Full Text] [Related]
15. Epstein Barr virus/complement C3d receptor is an interferon alpha receptor.
Delcayre AX; Salas F; Mathur S; Kovats K; Lotz M; Lernhardt W
EMBO J; 1991 Apr; 10(4):919-26. PubMed ID: 1849076
[TBL] [Abstract][Full Text] [Related]
16. Role of complement receptor type 2 and endogenous complement in the humoral immune response to conjugates of complement C3d and pneumococcal serotype 14 capsular polysaccharide.
Mitsuyoshi JK; Hu Y; Test ST
Infect Immun; 2005 Nov; 73(11):7311-6. PubMed ID: 16239528
[TBL] [Abstract][Full Text] [Related]
17. Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23.
Cordier M; Calender A; Billaud M; Zimber U; Rousselet G; Pavlish O; Banchereau J; Tursz T; Bornkamm G; Lenoir GM
J Virol; 1990 Mar; 64(3):1002-13. PubMed ID: 2154588
[TBL] [Abstract][Full Text] [Related]
18. Studies of the Epstein Barr virus receptor found on Raji cells. II. A comparison of lymphocyte binding sites for Epstein Barr virus and C3d.
Hutt-Fletcher LM; Fowler E; Lambris JD; Feighny RJ; Simmons JG; Ross GD
J Immunol; 1983 Mar; 130(3):1309-12. PubMed ID: 6218205
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a complement receptor 2 (CR2, CD21) ligand binding site for C3. An initial model of ligand interaction with two linked short consensus repeat modules.
Molina H; Perkins SJ; Guthridge J; Gorka J; Kinoshita T; Holers VM
J Immunol; 1995 May; 154(10):5426-35. PubMed ID: 7730644
[TBL] [Abstract][Full Text] [Related]
20. A minimum CR2 binding domain of C3d enhances immunity following vaccination.
Bower JF; Ross TM
Adv Exp Med Biol; 2006; 586():249-64. PubMed ID: 16893077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
